Research programme: MRI contrast agents - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: MRI contrast agents - Bayer HealthCare Pharmaceuticals

Alternative Names: gadofluorine derivatives; gadofluorine-M; gadofluorine-P

Latest Information Update: 22 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma; EPIX Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Contrast media; Lanthanoid series elements; Organometallic compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer metastases; Vascular disorders

Most Recent Events

  • 20 Apr 2010 Preclinical trials in Cancer metastases in Germany (Parenteral)
  • 20 Apr 2010 Pharmacodynamics data from a preclinical study in Cancer metastases presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
  • 02 Apr 2008 Research programme is still in preclinical trials for Vascular disorders in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top